Annals of Surgical Oncology, Vol 4, Issue 3 215-222, Copyright © 1997 by Society of Surgical Oncology

ARTICLES

Surgically debulked malignant pleural mesothelioma: results and prognostic factors

H. I. Pass, K. Kranda, B. K. Temeck, I. Feuerstein and S. M. Steinberg
Thoracic Oncology Section, National Cancer Institute/National Institutes of Health, Bethesda, Maryland 20892, USA.

BACKGROUND: We analyzed morbidity and mortality, sites of recurrence, and possible prognostic factors in 95 (78 male, 17 female) patients with MPM on phase I-III trials since 1990. A debulking resection to a requisite, residual tumor thickness of < or = 5 mm was required for inclusion. METHODS: Preoperative tumor volumes were determined by three-dimensional reconstruction of chest computerized tomograms. Pleurectomy (n = 39) or extrapleural pneumonectomy (EPP; n = 39) was performed. Seventeen patients could not be debulked. Preoperative EPP platelet counts (404,000) and mean tumor volume (491 cm3) were greater than that seen for pleurectomy (344,000, 114 cm3). RESULTS: Median survival for all patients was 11.2 months, with that for pleurectomy 14.5 months, that for EPP 9.4 months, and that for unresectable patients 5.0 months. Arrhythmia (n = 14; 15%) was the most common complication, and there were two deaths related to surgery (2.0%). Tumor volume of > 100 ml, biphasic histology, male sex, and elevated platelet count were associated with decreased survival (p < 0.05). Both EPP and pleurectomy had equivalent recurrence rates (27 of 39 [69%] and 31 of 39 [79%], respectively); however, 17 of 27 EPP recurrences as opposed to 28 of 31 pleurectomy recurrences were locoregional (p2 = 0.013). CONCLUSIONS: Debulking resections for MPM can be performed with low operative mortality. Size and platelet count are important preoperative prognostic parameters for MPM. Patients with poor prognostic indicators should probably enter nonsurgical, innovative trials where toxicity or response to therapy can be evaluated.

This article has been cited by other articles:

				A. Nakas, D. S. Trousse, A. E. Martin-Ucar, and D. A. Waller Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy Eur. J. Cardiothorac. Surg., October 1, 2008; 34(4): 886 - 891. [Abstract] [Full Text] [PDF]

				P. H. Schipper, F. C. Nichols, K. M. Thomse, C. Deschamps, S. D. Cassivi, M. S. Allen, and P. C. Pairolero Malignant Pleural Mesothelioma: Surgical Management in 285 Patients Ann. Thorac. Surg., January 1, 2008; 85(1): 257 - 264. [Abstract] [Full Text] [PDF]

				D. C. Rice, C. W. Stevens, A. M. Correa, A. A. Vaporciyan, A. Tsao, K. M. Forster, G. L. Walsh, S. G. Swisher, W. L. Hofstetter, R. J. Mehran, et al. Outcomes After Extrapleural Pneumonectomy and Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma Ann. Thorac. Surg., November 1, 2007; 84(5): 1685 - 1693. [Abstract] [Full Text] [PDF]

				R. B. Cameron Extrapleural Pneumonectomy Is the Preferred Surgical Management in the Multimodality Therapy of Pleural Mesothelioma: Con Argument Ann. Surg. Oncol., April 1, 2007; 14(4): 1249 - 1253. [Full Text] [PDF]

				T. J. Barreiro and P. J. Katzman Malignant Mesothelioma: A Case Presentation and Review J Am Osteopath Assoc, December 1, 2006; 106(12): 699 - 704. [Abstract] [Full Text] [PDF]

				W. G. Richards, L. Zellos, R. Bueno, M. T. Jaklitsch, P. A. Janne, L. R. Chirieac, B. Y. Yeap, R. J. Dekkers, P. M. Hartigan, L. Capalbo, et al. Phase I to II Study of Pleurectomy/Decortication and Intraoperative Intracavitary Hyperthermic Cisplatin Lavage for Mesothelioma J. Clin. Oncol., April 1, 2006; 24(10): 1561 - 1567. [Abstract] [Full Text] [PDF]

				S. Neragi-Miandoab Multimodality approach in management of malignant pleural mesothelioma Eur. J. Cardiothorac. Surg., January 1, 2006; 29(1): 14 - 19. [Abstract] [Full Text] [PDF]

				T. Mukohara, G. Civiello, I. J. Davis, M. L. Taffaro, J. Christensen, D. E. Fisher, B. E. Johnson, and P. A. Janne Inhibition of the Met Receptor in Mesothelioma Clin. Cancer Res., November 15, 2005; 11(22): 8122 - 8130. [Abstract] [Full Text] [PDF]

				B. W. Robinson and R. A. Lake Advances in malignant mesothelioma. N. Engl. J. Med., October 13, 2005; 353(15): 1591 - 1603. [Full Text] [PDF]

				G. Xia, S. R. Kumar, R. Masood, M. Koss, C. Templeman, D. Quinn, S. Zhu, R. Reddy, V. Krasnoperov, and P. S. Gill Up-Regulation of EphB4 in Mesothelioma and Its Biological Significance Clin. Cancer Res., June 15, 2005; 11(12): 4305 - 4315. [Abstract] [Full Text] [PDF]

				D. J. Stewart, A. Martin-Ucar, J. E. Pilling, J. G. Edwards, K. J. O'Byrne, and D. A. Waller The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma Ann. Thorac. Surg., July 1, 2004; 78(1): 245 - 252. [Abstract] [Full Text] [PDF]

				R. J. Kruklitis, S. Singhal, P. Delong, V. Kapoor, D. H. Sterman, L. R. Kaiser, and S. M. Albelda Immuno-gene therapy with interferon-{beta} before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma J. Thorac. Cardiovasc. Surg., January 1, 2004; 127(1): 123 - 130. [Abstract] [Full Text] [PDF]

				P. DeLong, T. Tanaka, R. Kruklitis, A. C. Henry, V. Kapoor, L. R. Kaiser, D. H. Sterman, and S. M. Albelda Use of Cyclooxygenase-2 Inhibition to Enhance the Efficacy of Immunotherapy Cancer Res., November 15, 2003; 63(22): 7845 - 7852. [Abstract] [Full Text] [PDF]

				H. I. Pass Pleural mesothelioma in 2002: Going somewhere very slowly J. Thorac. Cardiovasc. Surg., December 1, 2002; 124(6): 1074 - 1077. [Full Text]

				P. A. Janne, M. L. Taffaro, R. Salgia, and B. E. Johnson Inhibition of Epidermal Growth Factor Receptor Signaling in Malignant Pleural Mesothelioma Cancer Res., September 15, 2002; 62(18): 5242 - 5247. [Abstract] [Full Text] [PDF]

				V. W. Rusch, K. Rosenzweig, E. Venkatraman, L. Leon, A. Raben, L. Harrison, M. S. Bains, R. J. Downey, and R. J. Ginsberg A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma J. Thorac. Cardiovasc. Surg., October 1, 2001; 122(4): 788 - 795. [Abstract] [Full Text] [PDF]

				J. R. Roberts Surgical Treatment of Mesothelioma: Pleurectomy* Chest, December 1, 1999; 116(suppl_3): 446S - 449S. [Abstract] [Full Text] [PDF]

				V. W. Rusch and E. S. Venkatraman Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically Ann. Thorac. Surg., November 1, 1999; 68(5): 1799 - 1804. [Abstract] [Full Text] [PDF]

				D. H. Sterman, L. R. Kaiser, and S. M. Albelda Advances in the Treatment of Malignant Pleural Mesothelioma Chest, August 1, 1999; 116(2): 504 - 520. [Abstract] [Full Text] [PDF]

				G. B. Ratto, D. Civalleri, M. Esposito, E. Spessa, A. Alloisio, F. D. Cian, and M. O. Vannozzi PLEURAL SPACE PERFUSION WITH CISPLATIN IN THE MULTIMODALITY TREATMENT OF MALIGNANT MESOTHELIOMA: A FEASIBILITY AND PHARMACOKINETIC STUDY J. Thorac. Cardiovasc. Surg., April 1, 1999; 117(4): 759 - 765. [Abstract] [Full Text] [PDF]

				H. I. Pass, B. K. Temeck, K. Kranda, S. M. Steinberg, and I. R. Feuerstein Preoperative Tumor Volume Is Associated With Outcome In Malignant Pleural Mesothelioma J. Thorac. Cardiovasc. Surg., February 1, 1998; 115(2): 310 - 318. [Abstract] [Full Text]